
Eli Lilly and Company, Merck & Co., Inc., and Johnson & Johnson are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription or over-the-counter medicines. For stock market investors, these stocks represent ownership in pharmaceutical businesses and may offer growth potential, though they are also affected by drug approvals, clinical-trial results, patents, regulations, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read Our Latest Research Report on LLY
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Read Our Latest Research Report on MRK
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read Our Latest Research Report on JNJ
Recommended Stories
- MarketBeat’s Top Five Stocks to Own in October 2026
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
- Insiders Are Selling These 5 AI Stocks—Should You Worry?
- 3 Companies With Room to Pass on Costs to Manage Inflation
- Not All Tech Is Getting Crushed: 5 Names Holding Up Through the AI Sell-Off
